Kida Keisuke, Nishitani-Yokoyama Miho, Shimada Kazunori, Daida Hiroyuki, Ushijima Akiko, Kono Yuji, Miura Masanobu, Itoh Hidetaka, Sakata Yasuhiko, Nagayama Masatoshi, Furukawa Yutaka, Fukuma Nagaharu, Izawa Hideo, Ohya Yusuke, Saku Keijiro, Miura Shin-Ichiro, Goto Yoichi, Itoh Haruki, Makita Shigeru
Department of Pharmacology, St. Marianna University School of Medicine Kawasaki Japan.
Department of Cardiovascular Biology and Medicine, Juntendo University Graduate School of Medicine Tokyo Japan.
Circ Rep. 2022 Oct 15;4(11):550-554. doi: 10.1253/circrep.CR-22-0071. eCollection 2022 Nov 10.
Guidelines for the prevention and management of cardiovascular disease (CVD) highly recommend cardiac rehabilitation (CR) on the basis of abundant evidence of its effectiveness. However, the current understanding and dissemination of CR in Japan are far from sufficient. The Japanese Association of Cardiac Rehabilitation Registry (J-CARRY) is an academic society-led prospective multicenter observational registry conducted by the Registration and Facility Accreditation System Committee of the Japanese Association of Cardiac Rehabilitation. Data are collected prospectively using an electronic data capture system. Items related to patients' clinical background and CR, as well as mortality and major adverse cardiac and cerebrovascular events, will be collected in all cases. This Registry started in May 2014, and the number of participating medical institutions is expected to increase to >30; the targeted number of cases exceeded 3,000 per year as of April 30, 2022. Focusing on late Phase II data collection is a novel and significantly different approach compared with previous studies. The results of this study are currently under investigation. J-CARRY will provide real-world data regarding the current status and prognosis of CVD in patients who undergo Phase II CR in Japan.
心血管疾病（CVD）预防与管理指南基于大量有效性证据，强烈推荐心脏康复（CR）。然而，目前日本对CR的理解和推广还远远不够。日本心脏康复注册协会（J-CARRY）是一个由学术协会主导的前瞻性多中心观察性注册项目，由日本心脏康复协会注册与机构认证系统委员会开展。数据通过电子数据采集系统前瞻性收集。所有病例均会收集与患者临床背景和CR相关的项目，以及死亡率和主要不良心脑血管事件。该注册项目于2014年5月启动，预计参与的医疗机构数量将增至30多家；截至2022年4月30日，每年的目标病例数超过3000例。与以往研究相比，专注于II期后期的数据收集是一种新颖且显著不同的方法。本研究结果目前正在调查中。J-CARRY将提供关于日本接受II期CR患者CVD现状和预后的真实世界数据。
